CN109942503A - A kind of micromolecular inhibitor AZIN18 and its application in pharmacy - Google Patents
A kind of micromolecular inhibitor AZIN18 and its application in pharmacy Download PDFInfo
- Publication number
- CN109942503A CN109942503A CN201910273003.5A CN201910273003A CN109942503A CN 109942503 A CN109942503 A CN 109942503A CN 201910273003 A CN201910273003 A CN 201910273003A CN 109942503 A CN109942503 A CN 109942503A
- Authority
- CN
- China
- Prior art keywords
- azin18
- cell
- micromolecular inhibitor
- drug
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a kind of micromolecular inhibitor AZIN18, the structural formula of the micromolecular inhibitor are as follows:Application of the present invention by the micromolecular inhibitor AZIN18 on the drug that preparation inhibits antienzyme inhibiting factor.As the result is shown: AZIN18 inhibits human prostata cancer PC3 cell Proliferation, reduces intracellular ODC albumen and polyamine content, changes PC3 cell growth cycle, while inducing PC3 apoptosis.
Description
Technical field
The present invention provides a kind of micromolecular inhibitor for inhibiting antienzyme inhibiting factor, while the micromolecular inhibitor being used for
Application on the drug of preparation treatment tumor disease.
Background technique
Polyamines is the basic regulator of cell growth and development, and the precision control to Polyamine Metabolism is normal activities institute
It is required.The study found that Polyamine Metabolism imbalance and a variety of diseases, including cancer, inflammation, atherosclerosis, apoplexy, kidney failure and
The generation of diabetes etc. and development are closely related.The quick division of cell is highly dependent on intracellular polyamine content, thus swells
Also conspicuousness is higher than normal cell to total polyamine content in oncocyte.The study found that the raising of intracellular polyamine level can promote to swell
Tumor growth and invasion transfer, and tumor cell proliferation can be inhibited by reducing polyamine content then, thus regulate and control Polyamine Metabolism approach
Important means as treatment and prevention of tumour.
Under normal physiological conditions, intracellular polyamine content is regulated and controled by complicated synthesis, catabolism and transporting mechanism,
Since polyamines anabolism rate-limiting enzyme ODC plays most important effect in control intracellular polyamine content, thus to the enzyme tune
The research of control is also the most deep.Antienzyme (antizyme, AZ) is intracellular naturally occurring ODC inhibiting factor, it passes through dual
The intracellular polyamine level of effects: (1) forming heterodimer in conjunction with ODC and accelerates its degradation, thus closes ODC activity
It is synthesized with intracellular polyamine is reduced；(2) in conjunction with the polyamine transport carrier on cell membrane, thus inhibit more in extracellular environment
Amine is shifted to intracellular.Intracellular AZ activity is simultaneously again by another factor, antienzyme inhibiting factor (antizyme
Inhibitor, AZIN) adjusting, AZIN forms heterodimer with higher affinity and AZ, and thus competitive release is caught by AZ
The ODC that obtains simultaneously restores its activity.In addition, intracellular polyamine content is to influence the active another key factor of AZ, high Concentrations of Polyamines
Functional AZ protein molecular can be synthesized and inducing a kind of special frame-shift translation mechanism.Therefore, exist into the cell it is a kind of with
AZ-AZIN is the ODC regulated and control network of core, is ideal polyamines regulatory molecule target spot.
It is on cellular level the study found that being with difluoromethylornithine (difluoromethylormithine, DFMO)
The ODC inhibitor of representative can exhaust intracellular polyamine by closing ODC activity, thus inhibit tumor cell proliferation and induce swollen
Apoptosis of tumor.But these inhibitor for being directly targeted ODC are used for clinical unsatisfactory curative effect as anti-tumor drug, study carefully its original
Cause, first is that these drugs need high dose to use, the side effect for thus bringing patient to be difficult to bear, second is that working as intracellular polyamines
After synthesis is suppressed, the polyamines in extracellular environment can pass through the polyamine transport carrier (polyamine on cell membrane
Transport) enter cell and it is compensatory into the cell by synthesize inhibit caused by polyamine content decline.Exploration is new as a result, to press down
The active method of ODC processed and approach, become the research hotspot in the field, have important clinical meaning and application prospect.
Summary of the invention
The purpose of the present invention, be using in the regulated and control network AZ and AZIN as molecular target, with area of computer aided drug
Designing technique designs and screens a kind of AZIN inhibitor, interferes the interaction of AZ-AZIN, reduces intracellular ODC and polyamines
Level can be used for preparing the drug for the treatment of tumour.
The concrete structure formula of micromolecular inhibitor AZIN18 are as follows:
Application of the micromolecular inhibitor AZIN18 on the drug that preparation inhibits antienzyme inhibiting factor.
Application of the micromolecular inhibitor AZIN18 on the drug that preparation inhibits human prostata cancer.
The preparation inhibits the application on the drug of human prostata cancer, specifically inhibits human prostata cancer PC3 in preparation
Application on the drug of cell growth and breeding.
Detailed description of the invention
The Pharmacophore Model of Fig. 1 screening AZIN micromolecular inhibitor.
The variation of Fig. 2 Western blot detection intracellular ODC, AZ-1, AZIN-1 protein content of PC3.
Fig. 3 HPLC detects the content of PC3 intracellular polyamine, * *: p < 0.01, *: p < 0.05.
Fig. 4 mtt assay detects small-molecule drug AZIN18 in different time to PC3 cell growth inhibition.
The influence of Fig. 5 Flow cytometry small-molecule drug AZIN18 and control group to PC3 cell growth cycle.
Fig. 6 Flow cytometry small-molecule drug AZIN18 and control group induce the influence of PC3 Apoptosis respectively.
Specific embodiment
A kind of micromolecular inhibitor AZIN18, concrete structure formula are as follows:
Pharmacophore the selection result
With the crystal structure (3BTN.pdb) of AZIN for initial configuration, being found using pocket detecting module may in receptor
Binding site, have found 5 possible binding sites altogether.It is combined in conjunction with AZ and AZIN.The accidental data at interface has selected packet
The most pocket of residue containing combination interface is for further screening micromolecular inhibitor.With the crucial amino of determining active site
Based on sour residue feature, the Pharmacophore Model (Fig. 1) of pharmacophore method building binding pocket is utilized.Utilize the pharmacophore of building
SPECS compound database is screened in pattern search, and final purchase obtains AZIN18 compound.
The influence of micromolecular inhibitor AZIN18 ODC, AZ, AZIN and polyamine content intracellular to PC3
1. the variation of Western blot detection intracellular ODC, AZ-1, AZIN-1 protein content of PC3
Collect drug-treated cell and cellular control unit, and with RIPA cell pyrolysis liquid cracking half an hour after, through from
Albumen is collected after centrifugation with 12000rmp in scheming, after through BCA standard measure albumen.Then with the albumen of every group of equivalent through electrophoresis point
From rear, electrotransfer to pvdf membrane, with 5% skim milk (20mmol/L Tris-HCl, 150mmol/L NaCl, 0.05%
Tween-20, pH7.4) closing one hour after, with anti-ODC, AZIN-1 and AZ-1 monoclonal antibody be incubated overnight, afterwards with it is polyclonal
Antibody at room temperature is incubated for one hour.Pass through machine testing expressing quantity on ECL.As a result as shown in Fig. 2, compared with control cell,
ODC protein content significantly reduces, and prompts AZIN18 that can effectively interfere the interaction between AZ and AZIN albumen, accelerates ODC's
Degradation, to reduce the content of ODC albumen in cell.
2.HPLC detects influence of the AZIN18 to polyamine content in human prostata cancer PC3 cell
The cell and cellular control unit for collecting drug-treated are cracked after obtaining albumen with RIPA cell pyrolysis liquid, are passed through
Polyamines is extracted after benzoylation reaction, and passes through 2695 type high performance liquid chromatograph of Waters, 2489UV/Vis type array detection
Device and MYC chromatographic column (150mmx4.6mm, 5 μm), with acetonitrile-water (40:60), flow velocity 1.0mL/min, 254nm and room temperature (column
Temperature) under conditions of detect polyamine content.The results show that compared with control cell, putrescine and spermine in cell after AZIN18 processing
Content is reduced, and shows AZIN18 interference cellular polyamine metabolism, as shown in Figure 3.
Micromolecular inhibitor AZIN18 antitumor activity
AZIN18 effectively inhibits the growth and breeding of human prostata cancer PC3 cell
The PC3 cell of logarithmic growth phase is with 4 × 103The concentration in a/hole is inoculated with 96 porocyte culture plates, after culture for 24 hours,
1640 culture mediums containing small-molecule drug AZIN18 are added into cell hole respectively, making the final concentration of AZIN18 is respectively 12.5
μM, 25 μM, 50 μM, 75 μM and 100 μM (every group sets 4 multiple holes).It is equipped with not dosing control group and blank group simultaneously.Respectively after
Continuous culture for 24 hours, after 48h and 72h, removes cell culture medium in culture plate, is added the MTT reagent of final concentration of 0.2g/L, and 37 DEG C
It is incubated for after 4h plus 150 μ L of DMSO, concussion measure the absorbance value at 570nm after mixing.Cell proliferation inhibition rate=(A control
Hole-A experimental port)/A control wells × 100%.
Mtt assay detects SLD9059 to the inhibiting effect of A549 cell, and all concentration No. AZIN18 can show as the result is shown
The growth (P < 0.001) for inhibiting PC3 cell is write, and the growth of PC3 is increased as the concentration of drug increases inhibiting effect, and with
The time growth inhibition effect increase (P < 0.001) (Fig. 4).
Micromolecular inhibitor AZIN18 Anticancer Effect and Mechanism
1.AZIN18 changes human prostata cancer PC3 cell growth cycle
The PC3 cell of logarithmic growth phase is with 1.3 × 105The concentration in a/hole is inoculated in 6 porocyte culture plates, and culture is for 24 hours
Afterwards, 1640 culture mediums containing small-molecule drug AZIN18 are added into cell hole, make 42.5 μM of final concentration of AZIN18, simultaneously
Equipped with not dosing control group, two groups handle 48h.It is according to cell cycle detection kit specification processing cell and thin through streaming
Born of the same parents' instrument detects the cell cycle.The result shows that: AZIN18 can cause the PC3 cell G0/G1 phase to block (Fig. 5), be increased to by 64.16%
75.4% (P < 0.05).
2.AZIN18 induces human prostata cancer PC3 apoptosis
The PC3 cell of logarithmic growth phase is with 1.3 × 105The concentration in a/hole is inoculated in 6 porocyte culture plates, and culture is for 24 hours
Afterwards, 1640 culture mediums containing small-molecule drug AZIN18 are added into cell hole, make 42.5 μM of final concentration of AZIN18, simultaneously
Equipped with not dosing control group, two groups handle 48h.Cell is handled according to apoptosis kit specification, and through fluidic cell
Instrument detects Apoptosis situation.As a result such as Fig. 6: compared with control cell, viable apoptotic cell (AnnexinV+/PI-) ratio from
1.15% increases to 38.8%, and non-viable apoptotic cell (AnnexinV+/PI+) ratio increases to 19.3% from 1.87%, prompts
AZIN18 can effectively induce PC3 apoptosis.
Claims (4)
1. a kind of micromolecular inhibitor AZIN18, which is characterized in that the structural formula of the micromolecular inhibitor are as follows:
2. micromolecular inhibitor AZIN18 according to claim 1 is on the drug that preparation inhibits antienzyme inhibiting factor AZIN
Application.
3. micromolecular inhibitor AZIN18 according to claim 1 answering on the drug that preparation inhibits human prostata cancer
With.
4. application according to claim 3, which is characterized in that specifically inhibit the growth of human prostata cancer PC3 cell in preparation
Application on the drug of breeding.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910273003.5A CN109942503B (en) | 2019-04-04 | 2019-04-04 | Small molecule inhibitor AZIN18 and application thereof in pharmacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910273003.5A CN109942503B (en) | 2019-04-04 | 2019-04-04 | Small molecule inhibitor AZIN18 and application thereof in pharmacy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109942503A true CN109942503A (en) | 2019-06-28 |
| CN109942503B CN109942503B (en) | 2022-03-04 |
Family
ID=67013765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910273003.5A Active CN109942503B (en) | 2019-04-04 | 2019-04-04 | Small molecule inhibitor AZIN18 and application thereof in pharmacy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109942503B (en) |
-
2019
- 2019-04-04 CN CN201910273003.5A patent/CN109942503B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| 审查员: "STN Registry 数据库", 《STN检索报告》 * |
| 欧洁 等: "AZ/AZIN调控对A549非小细胞肺癌细胞作用研究", 《中国生物化学与分子生物学会第十二届全国会员代表大会暨2018年全国学术会议摘要集》 * |
| 欧洁 等: "鸟氨酸脱羧酶抗酶-1过表达促进非小细胞肺癌细胞系A549凋亡", 《基础医学与临床》 * |
| 金涛 等: "siＲNA靶向抗酶抑制剂下调前列腺癌细胞PC3中鸟氨酸脱羧酶表达", 《基础医学与临床》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109942503B (en) | 2022-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gottschalk et al. | Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells | |
| Kalid et al. | Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors | |
| Gidaro et al. | Eriocitrin and apigenin as new carbonic anhydrase VA inhibitors from a virtual screening of calabrian natural products | |
| Tai et al. | Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors | |
| Rasul et al. | Discovery of potential mTOR inhibitors from Cichorium intybus to find new candidate drugs targeting the pathological protein related to the breast cancer: an integrated computational approach | |
| Adhikari et al. | Exploring structural requirements of aurone derivatives as antimalarials by validated DFT-based QSAR, HQSAR, and COMFA–COMSIA approach | |
| Pinzi et al. | Identification of target associations for polypharmacology from analysis of crystallographic ligands of the Protein Data Bank | |
| CN109988086A (en) | A kind of micromolecular inhibitor AZIN30 and its application in pharmacy | |
| Shahinozzaman et al. | A computational approach to explore and identify potential herbal inhibitors for the p21-activated kinase 1 (PAK1) | |
| Ugbe et al. | Theoretical modeling and design of some pyrazolopyrimidine derivatives as Wolbachia inhibitors, targeting lymphatic filariasis and onchocerciasis | |
| Gouthami et al. | In-silico characterization of phytochemicals identified from Vitex negundo (L) extract as potential therapy for Wnt-signaling proteins | |
| Uddin et al. | Synthesis of new derivatives of benzylidinemalononitrile and ethyl 2-cyano-3-phenylacrylate: in silico anticancer evaluation | |
| CN109942503A (en) | A kind of micromolecular inhibitor AZIN18 and its application in pharmacy | |
| Shahin et al. | Ligand-based computer aided drug design reveals new tropomycin receptor kinase a (TrkA) inhibitors | |
| CN109988135A (en) | Small molecule inhibitor AZIN19 and application thereof in pharmacy | |
| CN109953986A (en) | A kind of micromolecular inhibitor AZIN53 and its application in pharmacy | |
| CN109942467A (en) | A kind of micromolecular inhibitor AZIN32 and its application in pharmacy | |
| Suaifan et al. | Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors | |
| Cutinho et al. | Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II) | |
| He et al. | In silico approaches using pharmacophore model combined with molecular docking for discovery of novel ULK1 inhibitors | |
| Akhtar et al. | Novel aglycones of steroidal glycoalkaloids as potent tyrosine kinase inhibitors: Role in VEGF and EGF receptors targeted angiogenesis | |
| Kandasamy et al. | Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes | |
| Varun et al. | Rohitukine content across the geographical distribution of Dysoxylum binectariferum Hook F. and its natural derivatives as potential sources of CDK inhibitors | |
| Murali et al. | Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapy | |
| Jiang et al. | Discovery of potential negative allosteric modulators of mGluR5 from natural products using pharmacophore modeling, molecular docking, and molecular dynamics simulation studies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |